Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

MLA

Margarita Mahindi, et al. “Amodiaquine, Its Desethylated Metabolite, or Both, Inhibit the Metabolism of Debrisoquine (CYP2D6) and Losartan (CYP2C9) in Vivo.” European Journal of Clinical Pharmacology, vol. 62, June 2006, pp. 539–46. EBSCOhost, https://doi.org/10.1007/s00228-006-0121-3.

APA

Margarita Mahindi, Maria Pihlsgard, Anna Nordmark, Lars L. Gustafsson, Agneta Wennerholm, & Leif Bertilsson. (2006). Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European Journal of Clinical Pharmacology, 62, 539–546. https://doi.org/10.1007/s00228-006-0121-3

Chicago

Margarita Mahindi, Maria Pihlsgard, Anna Nordmark, Lars L. Gustafsson, Agneta Wennerholm, and Leif Bertilsson. 2006. “Amodiaquine, Its Desethylated Metabolite, or Both, Inhibit the Metabolism of Debrisoquine (CYP2D6) and Losartan (CYP2C9) in Vivo.” European Journal of Clinical Pharmacology 62 (June): 539–46. doi:10.1007/s00228-006-0121-3.